



MEDICAL TIPS

DIABIZ TABLETS

Issue XII, No. 45, 2022

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon SD et al. New Engl J Med 2022; 387: 1089-1098.

- SGLT2 inhibitors reduce the risk of hospitalization for heart failure and CV death among patients with chronic heart failure (HF) and LVEF of 40% or less, however, its efficacy in patients with higher or preserved LVEF needs to be evaluated.
- 6263 patients with HF and LVEF of more than 40% were divided to receive 10 mg of dapagliflozin once daily or matching placebo in addition to their usual therapy and the worsening of HF and CV death was assessed over time.
- Over a period of 2.3 years, a higher number of worsening of HF and incidence of CV death was observed in the placebo group as compared to the dapagliflozin group.
- Similar results were observed in patients with LVEF of 60% or more and in patients with LVEF of 60% or less.

Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction.

